Bristol Myers Squibb (BMY) Accumulated Depreciation & Amortization (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Accumulated Depreciation & Amortization data on file, last reported at $594.0 million in Q1 2026.

• Accumulated Depreciation & Amortization for Q1 2026 came in at $594.0 million, down 41.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $594.0 million (down 41.3% YoY), and the FY2025 annual result was $4.0 billion, down 58.22% from the prior year.
• Accumulated Depreciation & Amortization slipped to $594.0 million in Q1 2026 per BMY's latest filing, from $4.0 billion in the prior quarter.
• Over five years, Accumulated Depreciation & Amortization peaked at $10.3 billion in Q4 2022 and troughed at $594.0 million in Q1 2026.
• A 5-year average of $5.0 billion and a median of $4.9 billion in 2023 frame the typical range for Accumulated Depreciation & Amortization.
• The sharpest annual moves came in 2024 and 2025: Accumulated Depreciation & Amortization gained 5.81% in 2024, then tumbled 60.7% in 2025.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $10.3 billion in 2022, then declined by 5.02% to $9.8 billion in 2023, then fell by 1.64% to $9.6 billion in 2024, then slumped by 58.22% to $4.0 billion in 2025, then plunged by 85.19% to $594.0 million in 2026.
• Business Quant data shows BMY's Accumulated Depreciation & Amortization at $594.0 million in Q1 2026, $4.0 billion in Q4 2025, and $3.0 billion in Q3 2025.